Regional Blood FlowNCT02978560
Indocyanine Green Tissue Perfusion Monitoring
An observational study of Regional Blood Flow and Wound Heal, run by University of Maryland, Baltimore at 1 site in United States.
Trial summary
The aim of this project is to demonstrate that fluorescence-mediated photoplethysmography (FM-PPG) is capable of routinely acquiring the tissue perfusion data sufficient to detect and monitor skin tissue perfusion anomalies. Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Regional Blood Flow, Wound Heal
- What is being tested?
- fluorescence-mediated photoplethysmography
- Type of treatment
- Injection or infusion
- How many people
- 15 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Mar 2018to 1 Jul 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 60
Who may be able to join
- Male or female subjects, of any ethnic background, who are at least 21 years of age and have normal healthy skin (30 normal subjects) or patients with diabetic foot ulcer lesions (30 patients).
- All subjects must be willing and be able to comply with the protocol, and to provide informed consent.
Who cannot join
- Patient currently participating in any other drug or device investigational study.
- Patient with significant liver or kidney disease.
- Patient with known adverse reaction to indocyanine green or iodine.
- Patient is pregnant or nursing.
- Patient with peripheral vascular disease and an ankle-brachial index blood flow of 0.6 or less
Trial locations and contacts
1 site in 1 country.
United States1 site
Baltimore Medical & Surgical Associates PA
Towson, Maryland, 21204
About this study
The aim of this project is to demonstrate that fluorescence-mediated photoplethysmography (FM-PPG) is capable of routinely acquiring the tissue perfusion data sufficient to detect and monitor skin tissue perfusion anomalies.
Read the detailed description
Methods to reliably predict which cutaneous wounds will heal are unreliable and clinical judgment inadequate. This is a problem for all health care providers and a common dilemma when evaluating patients in the Emergency Department. While capillary blood perfusion of the skin is a recognized requirement for healing, objective methods to reliably quantify this necessary physiological parameter are lacking. In large part, this is due to difficulties visualizing and recording capillary blood flow. Despite technical advances in blood flow imaging the capillary circulation remains poorly characterized. That is, current methodology can only image medium-to-large caliber vessels, not the small capillaries. The investigators hypothesize that with new technology, objective assessment of capillary flow can be achieved with fluorescence-mediated photoplethysmography (FM-PPG) methodology, and this evaluation can be used to objectively determine which wounds will heal promptly versus require adjunctive interventions.
FM-PPG is currently being used clinically in clinics worldwide as a way to image blood flow, but the apparatus provides only a relative measurement. Thus, this investigation is Observational in nature and not Interventional. With repeated evaluations over weeks, current FM-PPG allows an assessment to be made on whether wound conditions are improving. The investigators have a device containing new imaging software which, in theory, can offer precise quantification of capillary blood flow. If true, a single measurement may provide the data necessary to predict which patients are in danger of not healing and thus requiring aggressive, and at times expensive or painful interventions and - even worse - limb amputations. This protocol is to test proof-of-concept by first evaluating cutaneous capillary follow in 30 normal, healthy individuals and then 30 individuals presenting for treatment with a variety of skin wounds to a clinic.
FM-PPG methodology requires intravenous injection of a small amount of a fluorescent dye, indocyanine green (ICG). ICG is an FDA-approved agent that has been safely used in over 4000 patients. The area of skin to be measured is positioned below a camera and low-power laser instrument to take fluorescent pictures. The ICG is dissolved in sterile salt water for injection and about one and one half tablespoons injected into a vein. Typically, the measuring sequence consists of obtaining fluorescence images at the rate of approximately 30/second during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences are then acquired during the next half-hour, but without any additional injections. At about 60 seconds following dye injection, about two teaspoons of venous blood is withdrawn. This blood is used in the laboratory to determine the ICG dye concentration as a verification of the concentration determined by the camera images as part of the FM-PPG software algorithm (circulating dye concentration is needed in calculation of quantitative blood perfusion).
Since this study will be the first to employ a methodology capable of acquiring absolute tissue blood perfusion data from multiple subjects, there exists no database to indicate the normal range of variation in skin tissue perfusion that occurs in normal subjects. Since abnormal perfusion cannot be clearly recognized until the normal range of variation has been established, the first 30 subjects will be normal individuals. Then the following 30 subjects will be patients undergoing wound healing therapy.
- Conditions
- Regional Blood Flow, Wound Heal
- Being tested
- fluorescence-mediated photoplethysmography
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
fluorescence-mediated photoplethysmographyDiagnostic test
Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
| Study group | Role | What they receive |
|---|---|---|
| control | The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once. Receives: Diagnostic Test: fluorescence-mediated photoplethysmography | |
| Wound Group | The source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care. Receives: Diagnostic Test: fluorescence-mediated photoplethysmography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Indocyanine Green Tissue Perfusion Monitoring
Flow measurements on normal skin and sites of diabetic neuropathic wounds
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2016 (estimated)
- Study start5 Mar 2018
- Primary completion28 Jun 2018
- Study completion1 Jul 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Regional Blood FlowStudies of the same condition, open and under way.
- More trials run by University of Maryland, BaltimoreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Maryland, Baltimore
- Sponsor type
- University, hospital or other
- Collaborators
- Baltimore Medical & Surgical Associates PA
- Responsible party
- Principal investigator, Stephen R Thom, University of Maryland, Baltimore
- Investigators
- Stephen R Thom, MD, PhD, Principal investigator, University of Maryland, Baltimore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02978560
- Sponsor's protocol ID
- HP-00071920
- Status last verified
- Nov 2024
- First submitted
- 23 Nov 2016
- Last updated
- 27 Nov 2024
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Flower RW, Mirza Z, Thom SR. Absolute quantification (ml blood/sec * mm2 tissue) of normal vs. diabetic foot skin microvascular blood perfusion: Feasibility of FM-PPG measurements under clinical conditions. Microvasc Res. 2019 May;123:58-61. doi: 10.1016/j.mvr.2018.12.004. Epub 2018 Dec 24.
PubMed 30590061
Study at a glance
From the registry record, last updated by the sponsor on 27 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Indocyanine Green Tissue Perfusion Monitoring
- ClinicalTrials.gov ID
- NCT02978560
- Acronym / sponsor ID
- HP-00071920
- Conditions
- Regional Blood Flow, Wound Heal
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- University of Maryland, BaltimoreUniversity, hospital or other
- Collaborators
- Baltimore Medical & Surgical Associates PA
- Study start
- 5 Mar 2018 (actual)
- Primary completion
- 28 Jun 2018 (actual)
- Study completion
- 1 Jul 2018 (actual)
- First posted
- 1 Dec 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this project is to demonstrate that fluorescence-mediated photoplethysmography (FM-PPG) is capable of routinely acquiring the tissue perfusion data sufficient to detect and monitor skin tissue perfusion anomalies.
Detailed description
Methods to reliably predict which cutaneous wounds will heal are unreliable and clinical judgment inadequate. This is a problem for all health care providers and a common dilemma when evaluating patients in the Emergency Department. While capillary blood perfusion of the skin is a recognized requirement for healing, objective methods to reliably quantify this necessary physiological parameter are lacking. In large part, this is due to difficulties visualizing and recording capillary blood flow. Despite technical advances in blood flow imaging the capillary circulation remains poorly characterized. That is, current methodology can only image medium-to-large caliber vessels, not the small capillaries. The investigators hypothesize that with new technology, objective assessment of capillary flow can be achieved with fluorescence-mediated photoplethysmography (FM-PPG) methodology, and this evaluation can be used to objectively determine which wounds will heal promptly versus require adjunctive interventions.
FM-PPG is currently being used clinically in clinics worldwide as a way to image blood flow, but the apparatus provides only a relative measurement. Thus, this investigation is Observational in nature and not Interventional. With repeated evaluations over weeks, current FM-PPG allows an assessment to be made on whether wound conditions are improving. The investigators have a device containing new imaging software which, in theory, can offer precise quantification of capillary blood flow. If true, a single measurement may provide the data necessary to predict which patients are in danger of not healing and thus requiring aggressive, and at times expensive or painful interventions and - even worse - limb amputations. This protocol is to test proof-of-concept by first evaluating cutaneous capillary follow in 30 normal, healthy individuals and then 30 individuals presenting for treatment with a variety of skin wounds to a clinic.
FM-PPG methodology requires intravenous injection of a small amount of a fluorescent dye, indocyanine green (ICG). ICG is an FDA-approved agent that has been safely used in over 4000 patients. The area of skin to be measured is positioned below a camera and low-power laser instrument to take fluorescent pictures. The ICG is dissolved in sterile salt water for injection and about one and one half tablespoons injected into a vein. Typically, the measuring sequence consists of obtaining fluorescence images at the rate of approximately 30/second during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences are then acquired during the next half-hour, but without any additional injections. At about 60 seconds following dye injection, about two teaspoons of venous blood is withdrawn. This blood is used in the laboratory to determine the ICG dye concentration as a verification of the concentration determined by the camera images as part of the FM-PPG software algorithm (circulating dye concentration is needed in calculation of quantitative blood perfusion).
Since this study will be the first to employ a methodology capable of acquiring absolute tissue blood perfusion data from multiple subjects, there exists no database to indicate the normal range of variation in skin tissue perfusion that occurs in normal subjects. Since abnormal perfusion cannot be clearly recognized until the normal range of variation has been established, the first 30 subjects will be normal individuals. Then the following 30 subjects will be patients undergoing wound healing therapy.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| control | – | Diagnostic Test: fluorescence-mediated photoplethysmographyThe source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once. |
| Wound Group | – | Diagnostic Test: fluorescence-mediated photoplethysmographyThe source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 60
Key inclusion criteria (2 listed)
- Male or female subjects, of any ethnic background, who are at least 21 years of age and have normal healthy skin (30 normal subjects) or patients with diabetic foot ulcer lesions (30 patients).
- All subjects must be willing and be able to comply with the protocol, and to provide informed consent.
Key exclusion criteria (5 listed)
- Patient currently participating in any other drug or device investigational study.
- Patient with significant liver or kidney disease.
- Patient with known adverse reaction to indocyanine green or iodine.
- Patient is pregnant or nursing.
- Patient with peripheral vascular disease and an ankle-brachial index blood flow of 0.6 or less
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| fluorescence-mediated photoplethysmographyIndocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections. | Diagnostic test | Wound Group, control |
Primary outcome
Indocyanine Green Tissue Perfusion Monitoring
Time frame: 2 years
Flow measurements on normal skin and sites of diabetic neuropathic wounds
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Nov 2024.
- Results publication: PubMed 30590061Flower RW, Mirza Z, Thom SR. Absolute quantification (ml blood/sec * mm2 tissue) of normal vs. diabetic foot skin microvascular blood perfusion: Feasibility of FM-PPG measurements under clinical conditions. Microvasc Res. 2019 May;123:58-61. doi: 10.1016/j.mvr.2018.12.004. Epub 2018 Dec 24.
- Individual participant dataSharing planned: No
Related trials for Regional Blood Flow
RecruitingObservational study
Studies of Blood Flow to the Brain During Thought
Healthy Volunteer
Not yet recruiting
TORCH-LATAM-003: Regional Advanced-Therapy Pathways for Congenital Heart Disease
Congenital Heart Disease, Advanced Heart Failure
Not yet recruiting
TORCH-LATAM-004: Regional Advanced-Therapy Pathways for Adults With Acquired or Structural Heart Disease
Advanced Heart Failure, Acquired Heart Disease
Not yet recruiting
Doppler Ultrasound Evaluation of the Effects of Exercise Combined With Kinesiology Taping on Local Hemodynamic Parameters
Peripheral Arterial Hemodynamics, Lower Extremity Blood Flow
Active, not recruiting
Comparative Effectiveness of Nursing Interventions: Using Buerger-Allen Exercises Versus Mechanical Compression Therapy on Lower Limb Perfusion and Peripheral Neuropathy Among Patients Undergoing Chemotherapy.
Polyneuropathies, Regional Blood Flow
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephen R Thom, MD, PhD principal investigator
University of Maryland, Baltimore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Regional Blood Flow and Wound Heal, run by University of Maryland, Baltimore at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Indocyanine Green Tissue Perfusion Monitoring (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02978560, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Nov 2024.